Stepwise release of biologically active HMGB1 during HSV-2 infection.
about
Oncolytic viruses as therapeutic cancer vaccinesOncolytic viruses as immunotherapy: progress and remaining challengesOsteocytes: master orchestrators of boneDengue virus infection mediates HMGB1 release from monocytes involving PCAF acetylase complex and induces vascular leakage in endothelial cells.The potential role of HMGB1 release in peritoneal dialysis-related peritonitis.Soluble HMGB1 is a novel adipokine stimulating IL-6 secretion through RAGE receptor in SW872 preadipocyte cell line: contribution to chronic inflammation in fat tissueHepatitis C virus infection is blocked by HMGB1 released from virus-infected cells.HMGB1 Is a Potential Biomarker for Severe Viral Hemorrhagic FeversLife after death: targeting high mobility group box 1 in emergent cancer therapies.HMGB1 Promotes Hepatitis C Virus Replication by Interaction with Stem-Loop 4 in the Viral 5' Untranslated Region.Learning from the messengers: innate sensing of viruses and cytokine regulation of immunity - clues for treatments and vaccines.Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity.Sensing herpes: more than toll.Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments.Respiratory Syncytial Virus Infection Triggers Epithelial HMGB1 Release as a Damage-Associated Molecular Pattern Promoting a Monocytic Inflammatory Response.Immunogenic cell death by oncolytic herpes simplex virus type 1 in squamous cell carcinoma cells.Porcine epidemic diarrhea virus nucleoprotein contributes to HMGB1 transcription and release by interacting with C/EBP-β.Oncolytic Virotherapy and the Tumor Microenvironment.Supporting cells regulate the remodelling of aminoglycoside-injured organ of Corti, through the release of high mobility group box 1.High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy.From Benchtop to Bedside: A Review of Oncolytic Virotherapy.
P2860
Q21245758-73FD5CA2-4E10-455C-9535-DD8AE9C32333Q26745942-88F37EF2-14E0-4B3E-8177-FC6C92F7E5E1Q27022407-1AFF660D-BA00-4530-9055-4F90601EFD5AQ34364315-EFB96364-2E95-4ACA-B40D-485F81733405Q34566252-6082CE42-2255-44E5-B4D7-C2EB52450AD2Q35000952-7447E0DD-17B6-4354-9D20-83328879AAB6Q35192763-D794E410-08DC-4B45-BD07-5251ED98C153Q36062318-973BED75-A11E-4D43-B704-7DE91A0FE44DQ36562901-CE207CC8-5B90-4468-B5EA-3A1583165A93Q36736824-F248444D-D348-4D45-B6AB-3A4D94D07F21Q36807121-35E358A4-BA85-4686-B152-DCD9D3641492Q37707676-D7AFF2AB-944E-4107-8328-C79814CEBDA2Q37948677-95BFBC27-CB64-46F7-986C-562A0CDBD397Q38119845-7D90CC6A-B884-4FD0-A5BA-5215C74116BCQ38751350-2E26EE10-7A30-41BC-8CCA-735E430985ABQ38785456-C47D2CBE-64DE-41F5-9FCD-CEB877BF8316Q39383222-E0836808-4B84-4AEC-AE80-5E22E73A6E16Q47560690-DB1A739B-BAA4-4850-AA30-B3C09F9E0343Q50852251-7D13529B-BFEA-4555-8370-09BFFB071F6DQ52726371-72E81E30-E93A-49B3-AE13-27826A435072Q53272922-12C58434-817E-45D4-A4AE-3B1BBCDAFAAF
P2860
Stepwise release of biologically active HMGB1 during HSV-2 infection.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Stepwise release of biologically active HMGB1 during HSV-2 infection.
@ast
Stepwise release of biologically active HMGB1 during HSV-2 infection.
@en
type
label
Stepwise release of biologically active HMGB1 during HSV-2 infection.
@ast
Stepwise release of biologically active HMGB1 during HSV-2 infection.
@en
prefLabel
Stepwise release of biologically active HMGB1 during HSV-2 infection.
@ast
Stepwise release of biologically active HMGB1 during HSV-2 infection.
@en
P2093
P2860
P1433
P1476
Stepwise release of biologically active HMGB1 during HSV-2 infection.
@en
P2093
Chloé Borde
Claire Gaillard
Hakim Hocini
Joël Gozlan
Vincent Maréchal
P2860
P304
P356
10.1371/JOURNAL.PONE.0016145
P407
P577
2011-01-19T00:00:00Z